New drug aims to stop immune attack after stem cell transplants
NCT ID NCT07246031
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant. Fifty adults with blood cancers like leukemia will receive six weekly doses of BPC2001 along with standard care. The goal is to see if the drug reduces the risk of aGVHD and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BPC2001 (also known as KRN-7000)
What this could lead to
If it works, this could point toward a new way to prevent a serious complication of stem cell transplants, making the procedure safer for more patients.
What could go wrong
This is an early phase 2b trial with only 50 participants, so results may not apply to everyone. The drug could cause side effects or fail to reduce graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••